Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action
about
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism.Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.Antibody responses to Cryptococcus neoformans in Indian patients with cryptococcosis.Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrationsReduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers.Serologic response to cell wall mannoproteins and proteins of Candida albicansImmunoregulation by capsular components of Cryptococcus neoformans.Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.Antibody immunity and invasive fungal infectionsA 77-kilodalton protein of Cryptococcus neoformans, a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis.Acute lethal toxicity following passive immunization for treatment of murine cryptococcosisReactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice.Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infectionMolecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.Protective murine monoclonal antibodies to Cryptococcus neoformansCryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.The capsule of the fungal pathogen Cryptococcus neoformans.Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responsesPharmacotherapy of cryptococcosis.Antibody-based therapies for emerging infectious diseases.Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection.Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies.Modulating host immune responses to fight invasive fungal infections.In vivo depletion of murine CD8 positive T cells impairs survival during infection with a highly virulent strain of Cryptococcus neoformans.
P2860
Q30424017-978F15F4-4386-40C6-A10C-BDE58A6476C6Q33556039-1BB701D2-A063-4D96-9141-E372E67B2740Q33693515-03786845-618D-4BEB-9EAE-B7C074C62D65Q33751411-4331ECA2-54FC-4012-A046-BDAC944BC27CQ33754371-0122EE2E-8DE0-41F9-A965-33D17FAE089FQ33755308-00C60E4E-0D44-4377-93E6-85DBB22A9B50Q33857658-500F4F76-04E8-4F1F-8AA3-705CEC54505CQ33909453-CF568DA0-3833-488B-B817-7BE6B5BA418AQ33975989-4A84007F-AA47-4260-B413-B399B6CEEC84Q33981451-B105A0B8-7D57-41D1-95FC-B1604AABF117Q33992594-2B338D82-64C9-41AC-9D89-ECB9AFE6BA61Q34155052-843F3882-42EE-4DFC-8720-48947DC63771Q35115708-9B941C35-B6F0-4D60-9553-FAAB6CF779DCQ35434901-940C387E-1975-4C19-A322-4B6FB11AE74EQ35447692-F23C406E-1703-46F5-83B0-1B04624088E0Q35546266-8A6C780E-3BD6-4A94-B506-25057FE85F8AQ35546751-B728AF17-1E17-4863-AC7F-40BAD88CE5C0Q35567548-A9E83EBD-36C8-40AB-A392-9C838C9A1FDEQ35775466-16BC0FC1-F07B-459C-A2B4-BE8CD90C7950Q36047782-39EC4201-86F9-415E-A64F-E58CA6B2AB7EQ36255421-BD58F5CA-BAE0-4CC6-931E-9F1121DE53FBQ36361541-334169B8-68CE-4804-B130-5C08A4A71EE6Q36969771-E31B3F00-C13B-42E9-B3CB-260F161801ABQ36988205-432964BB-BB9C-44C6-B57F-E23C52DFB083Q37337879-EAC1F991-E0F1-439E-A6A4-2CFD887A5C8CQ37562226-A91F4E48-5335-4D7D-A654-56D640FFE949Q37587230-3C1235B1-DE77-4E8A-9C55-CEF9ECBE8599Q39228846-943CBD9D-9B6E-4472-9525-52BE9963765EQ39513175-02304E38-95B0-4F96-B84D-ED9605ED21FFQ39784797-70125FF3-8624-42DD-A99E-A9FE164469C0Q40375269-D819727E-472E-48DC-9F52-28384D57549EQ40673168-5406C565-CA54-4AB1-85EA-3AA6C708B96DQ46673081-7D365438-B34F-403E-830E-2ACB977AE984Q48215341-C367ECF0-1853-45C0-8CA3-726F7FA4B38D
P2860
Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action
description
1991 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1991
@ast
im Mai 1991 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: May 1991)
@en
vedecký článok (publikovaný 1991-05)
@sk
vědecký článek publikovaný v roce 1991
@cs
wetenschappelijk artikel (gepubliceerd in 1991-05)
@nl
наукова стаття, опублікована в травні 1991
@uk
научни чланак (објављен 1991-05)
@sr
name
Improved amphotericin B activi ...... cosis and mechanisms of action
@ast
Improved amphotericin B activi ...... cosis and mechanisms of action
@en
Improved amphotericin B activi ...... cosis and mechanisms of action
@nl
type
label
Improved amphotericin B activi ...... cosis and mechanisms of action
@ast
Improved amphotericin B activi ...... cosis and mechanisms of action
@en
Improved amphotericin B activi ...... cosis and mechanisms of action
@nl
prefLabel
Improved amphotericin B activi ...... cosis and mechanisms of action
@ast
Improved amphotericin B activi ...... cosis and mechanisms of action
@en
Improved amphotericin B activi ...... cosis and mechanisms of action
@nl
P356
P1476
Improved amphotericin B activi ...... cosis and mechanisms of action
@en
P2093
P304
P356
10.1093/INFDIS/163.5.1114
P407
P577
1991-05-01T00:00:00Z